Form 4: Tandem Diabetes Care Executive Trades Common Stock

Rick Carpenter, EVP & Chief Technology Officer at Tandem Diabetes Care Inc., reported transactions involving common stock, including acquisitions through an employee stock purchase plan and the withholding of shares for tax purposes.

Summary

• Rick Carpenter, EVP & Chief Technology Officer of Tandem Diabetes Care Inc. (TNDM), reported several transactions on May 15, 2026.
• These transactions include the acquisition of 1,437 shares of common stock at $0 cost, with 1,437 Restricted Stock Units (RSUs) also noted.
• Additionally, 732 shares were disposed of at $12.82, and 898 shares were acquired at $0 cost, with 898 RSUs noted.
• Further disposals of 457 shares at $12.82 and acquisitions of 6,439 shares at $0 cost, with 6,439 RSUs, were reported.
• The filing also notes the withholding of shares for tax purposes on the vesting of RSUs, with no shares sold in these instances.
• Carpenter voluntarily reported the acquisition of shares through the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP) for a purchase period ending May 15, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions and RSU vesting, with no significant positive or negative financial disclosures.

Positives

• Acquisition of 1,437 shares of common stock at no cost through RSUs.
• Acquisition of 898 shares of common stock at no cost through RSUs.
• Acquisition of 6,439 shares of common stock at no cost through RSUs.
• Voluntary reporting of share acquisition through the Employee Stock Purchase Plan (ESPP), indicating participation in company stock ownership.
• Shares withheld for tax withholding requirements on RSU vesting were not sold, preserving ownership.

Negatives

• Disposal of 732 shares at $12.82.
• Disposal of 457 shares at $12.82.
• Disposal of 3,277 shares at $12.82.

Future Outlook

The filing details the vesting schedules for Restricted Stock Units awarded in 2023, 2024, and 2025, with portions vesting on May 15, 2024, May 15, 2025, and May 15, 2026, respectively, followed by subsequent quarterly installments.

Management Comments

• The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2025, through May 15, 2026.
• Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for executives and directors to report changes in their beneficial ownership of company stock. These transactions, including RSU vesting and ESPP participation, are common compensation and incentive mechanisms within the medical device industry, aiming to align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The transactions reflect executive participation in company stock plans, which can align executive interests with shareholder value. The disposal of some shares may be for personal financial planning.
• Employees: The ESPP participation indicates opportunities for employees to acquire company stock.
• Management: The filing details compensation-related equity transactions for a key executive.

Next Steps

• Continued vesting of Restricted Stock Units as per the outlined schedules.
• Potential future transactions by the reporting person related to their equity holdings.

Key Dates

Keywords

Form 4, Tandem Diabetes Care, TNDM, Insider Trading, Stock Options, Restricted Stock Units, Employee Stock Purchase Plan, Executive Compensation, SEC Filing, Beneficial Ownership